News
EDSA
--
0.00%
--
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtua...
ACCESSWIRE · 3d ago
EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Enrollment for Phase 2b Trial of EB01 Estimated to Complete in 4Q22 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to eva...
Zacks Small Cap Research · 3d ago
Here's Why We're Not At All Concerned With Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 5d ago
Edesa Biotech GAAP EPS of -$0.33
Edesa Biotech press release (NASDAQ:EDSA): Q2 GAAP EPS of -$0.33. At March 31, 2022, Edesa had working capital of $14.66 million. Cash and cash equivalents totaled $15.89 million.
Seekingalpha · 05/13 13:07
BRIEF-Edesa Biotech Inc - For The Quarter Ended March 31, 2022, Co Reported A Net Loss Of $4.57 Million, Or $0.33 Per Common Share
reuters.com · 05/13 13:06
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 ...
ACCESSWIRE · 05/13 12:55
-- Earnings Flash (EDSA) EDESA BIOTECH Reports Q2 Loss $-0.33
MT Newswires · 05/13 09:05
Edesa Biotech Reports Dermatitis Study Enrolling Faster Than Expected
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient recruitment for a Phase 2b clinical study evaluating the
Benzinga · 04/28 11:47
Edesa Biotech Appoints Strategy Expert to Board of Directors
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M.
ACCESSWIRE · 03/29 13:00
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registered direct offerin...
ACCESSWIRE · 03/24 20:30
BRIEF-Edesa Biotech To Sell And Issue 1.5 Million Of Co's Common Shares
reuters.com · 03/23 21:09
Okta, ZIM Integrated Shipping Services, Upstart Holdings among premarket losers' pack
Applied Genetic Technologies (AGTC) -24% after proposes stock offering to fund clinical programs. ZIM Integrated Shipping Services (ZIM) -15%. Dave (DAVE) -13% on Q4 earnings release. Edesa Biotech (EDSA) -13% on pricing $10.0M stock offering. Dermata
Seekingalpha · 03/22 12:24
Edesa Biotech slips on ~$10M share offering
Edesa Biotech (NASDAQ:EDSA) has slipped ~17% pre-market after announcing a ~$10M share offering priced at-the-market under Nasdaq rules. The biopharmaceutical company entered into a definitive agreement with a single healthcare-focused institutional invest...
Seekingalpha · 03/22 12:19
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into a definitive agreement with a single hea...
ACCESSWIRE · 03/22 12:00
Edesa Biotech to Raise $10 Million in Direct Offering With Healthcare Investor -- Shares Fall
MT Newswires · 03/22 10:34
EDSA: Phase 3 Trial of EB05 Hits 25% Enrollment…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 3 Trial of EB05 Hits 25% Enrollment On February 17, 2022, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that more than 25% of the subjects have been randomized under the...
Zacks Small Cap Research · 02/18 12:05
Edesa Biotech Reports Enrollment Milestone In Phase 3 Study
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the
Benzinga · 02/17 13:02
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study eva...
ACCESSWIRE · 02/17 13:00
BRIEF-Edesa Biotech Inc- For Quarter Ended Dec 31, 2021, Reported Net Loss Of $0.33 Per Common Share
reuters.com · 02/14 14:56
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2021 ...
ACCESSWIRE · 02/14 14:00
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. It is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.